Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study
Scarisbrick, J. Arumainathan, A. Cowan, Richard DeSimone, J. Esler, C. Geskin, L. J. Goldaniga, M. Violetti, S. A. Mheidly, K. Morsia, E.
Scarisbrick, J.
Arumainathan, A.
Cowan, Richard
DeSimone, J.
Esler, C.
Geskin, L. J.
Goldaniga, M.
Violetti, S. A.
Mheidly, K.
Morsia, E.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Scarisbrick J, Arumainathan A, Cowan R, DeSimone J, Esler C, Geskin LJ, et al. Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S61-S2. PubMed PMID: WOS:001330761900121. English.